Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide for Refractory or Relapsed Aggressive B-cell Lymphomas

NCT01458366 is registered in ClinicalTrials.gov with Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University as lead sponsor.

NCT NCT01458366
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01458366 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide for Refractory or Relapsed Aggressive B-cell Lymphomas
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase
Phase 1/2
Overall status
Completed
Start date
November 9, 2011
Completion date
July 23, 2020
Enrollment
38 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin's lymphoma